

QUALITY POLICY

The Management of DB Biotech Inc. is obliged to implement all the applicable requirements of the ISO 9001:2015 and ISO 13485:2016 norms.

Management is aware of its responsibility for quality and safety of all offered products, and thus is establishing this Quality Policy.

Company's efforts regarding this subject are concentrated into the following four topics:

a/ Customer satisfaction

- Customers and their needs come first. We will strive to get their requirements right and to achieve their full satisfaction
- In the best possible way we will try to fulfill customers' realistic expectations
- We will help to achieve and improve all the employees' positive attitude towards customers' needs
- We will create all necessary preconditions for company's good name preservation and improvement.

b/ Quality and safety of the products

- Our ways to approach customers are: the quality of the product and the affordable price
- We will strive to build a correct and strong relationships with our partners; relationships based on long term sustainability, not a short term benefits
- We will always act based on agreed upon conditions between involved parties
- By a regular Critical Control Point monitoring we will ensure the best quality and safety of the final product is achieved
- By a regular continuing education (internal and/or external) we will try to achieve the high level of knowledge in the areas of quality management systems and laboratory work.

c/ Continuous improvement of the company's processes

- We will try to establish the environment for the employees where they can continuously grow and improve their quality of work
- By a constant monitoring of company's processes we will try to improve the work efficiency
- We will provide all necessary means to improve the company's quality management system
- We will make sure the latest trends in production of rabbit clonal monospecific antibodies are followed
- By a constant monitoring of the company's processes and by implications of its findings into particular steps we will strive to achieve a continuously improved quality management system.

d/ Company's cost effective measures

- We will be providing all necessary resources for continuous improvements of company's infrastructure
- All resources, material, financial and human must support continuous, viable and cost effective development of our company
- For these reasons we will implement and maintain measures allowing us to assess company's progress in these areas.

Ing. Peter Tkáč
CEO
DB Biotech, Inc.